(Q38328843)

2 September 2017

1 reference

title

New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases (English)

1 reference

2 September 2017

1 reference

Hidenori Fukuoka

1

1 reference

2 September 2017

publication date

1 April 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

18

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

274-278

1 reference

https://scigraph.springernature.com/pub.10.1007/s11102-015-0637-6

2 September 2017

exact match

0 references

cites work

The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Management of Cushing disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Medical management of Cushing's disease: what is the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Pituitary somatostatin receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Cabergoline monotherapy in the long-term treatment of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Effects of an Rb mutation in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Pituitary tumor transforming gene overexpression facilitates pituitary tumor development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Cell cycle regulation and neural differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Cyclins and their related proteins in pituitary tumourigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Oncogenic mutations as predictive factors in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Expression and function of ErbB receptors and ligands in the pituitary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Molecular pathways: CDK4 inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Mutations in the deubiquitinase gene USP8 cause Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-015-0637-6

Pathogenesis of pituitary tumors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25612787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25612787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25612787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11102-015-0637-6

1 reference

2 September 2017

1 reference